The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The potential of targeting mutant calreticulin with immunotherapy for the treatment of MPNs
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the potential of targeting mutant calreticulin with immunotherapy for the treatment of myeloproliferative neoplasms (MPNs). Prof. Rinaldi notes that while the data are still limited, the use of a monoclonal antibody to target a mutated protein in MPN is a novel concept, with promising results in terms of tolerability and response. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
